Gene editing startup seeks to create illness-free baby

A US biotech company, Preventive, backed by prominent investors including Sam Altman and Brian Armstrong, is reportedly pursuing a project to edit human embryos in order to eliminate hereditary illnesses. The startup was founded by gene‑editing scientist Lucas Harrington and aims to achieve a “biological first” by using the technology to create a child free of genetic disorders. While gene editing is already employed in postnatal treatments, editing embryos with the intent of creating babies is currently banned in the United States and many other countries.

Preventive’s stated goal is to “end hereditary disease by editing human embryos before birth,” a claim that has sparked intense debate over ethics, safety, and the potential for designer children. The company has been seeking locations where embryo editing is legal to conduct its research and recently announced that it has raised $30 million to explore the technology. The involvement of high‑profile investors such as Armstrong, the co‑founder of Coinbase, has drawn additional attention. Armstrong has discussed the possibility of using gene editing to produce children who are less prone to illness and has even suggested unveiling a healthy engineered baby to gain public acceptance of the practice.

Critics argue that such ventures risk crossing into eugenics, warning that the pursuit of “baby improvement” could have unintended consequences. The use of gene editing in human embryos is a highly contested issue, with many countries imposing strict regulations or outright bans. Proponents contend that the technology could lead to significant advances in preventing genetic diseases, while opponents raise concerns about potential risks and ethical implications.

As Preventive and other companies push forward with embryo‑editing research, the debate is likely to continue, with many calling for careful consideration and regulation of the technology. The development of gene‑editing tools such as CRISPR has progressed rapidly in recent years, enabling scientists to edit genes in living organisms. However, applying these tools to human embryos raises complex questions about the boundaries of scientific research and the consequences of tampering with human genetics. The international community will be watching closely as the discussion around Preventive’s project unfolds, weighing potential benefits against risks and ethical concerns.